|Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy Targets|
Zhi-jie Jey Cheng, Jamison Grailer, Pete Stecha, Jun Wang, Jim Hartnett, Frank Fan, and Mei Cong
Immune checkpoint receptors are promising new immunotherapy
targets for the treatment of a variety of diseases including cancer and
autoimmune-mediated disorders. We developed a suite of cell-based
bioluminescent reporter bioassays for individual and combination
immune checkpoint immunotherapy targets including: PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3, TIGIT, PD-1+TIGIT, GITR, 4-1BB, CD40, and OX40.
|A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue Sources|
Mira Genser-Nir, Sharon Daniliuc, Marina Tevrovsky, Roni Hazan Brill, Yuliya-Yael Miropolski, David Fiorentini.
An overview of a novel SF, XF differentiation system which enables achieving defined conditions for rapid generation of differentiated hMSCs towards tissue engineering and drug screening applications
|A Synthetic CRISPR-Cas9 System for Homology-directed Repair|
John A. Schiel, Maren M. Gross, Emily M. Anderson*, Eldon T. Chou, Anja van Brabant Smith Dharmacon, part of GE Healthcare, 2650 Crescent Drive, Lafayette, CO 80026, USA
Synthetic, dual-RNA-encoded Cas9 is used for precise homology-directed repair (HDR) gene engineering. Both short and long (GFP) inserts are covered.
|Deep Phenotyping - Harnessing Data Richness for Unsupervised High-Content Analysis|
Huang Dong, Wang Yi, Maciej Hermanowicz, Ke Yiping, Maja Choma, Lee Kee Khoon, Frederic Bard
Recognising the key challenges, we develop an end-to-end computational framework for HCA dubbed “Deep Phenotyping” that perform unsupervised analysis to leverage on the data richness for the discovery of unknown sub-phenotypes with minimal labeling cost.
|Clinical Applications of “Liquid biopsy” in the Colorectal Cancer Treatmen|
Koichi Suzuki, Yuji Takayama, Kosuke Ichida, Taro Fukui, Nao Kakizawa, Fumiaki Watanabe, Fumi Hasegawa, Rina Kikugawa, Shingo Tsujinaka, Yasuyuki Miyakura, Toshiki Rikiyama
Liquid biopsy provides a circulating biomarker not only for treatment response but decision making of a sequential strategy.
|Finite element modelling for the optimization of temperature control in Lab-on-a-Chip devices|
T. Pardy(a,b); T. Rang(a); I. Tulp(b)
The presented finite element model aims to help in the development of Lab-on-a-Chip devices which require temperature control. The model simulates the thermal system in such devices to enable in silico validation of designs and geometry optimization, and aims to be a versatile tool supporting multiple temperature control methods.
|Development of an Integrated Paper-based Molecular Diagnostic Platform|
Manoharanehru Branavan, Wamadeva Balachandran
The poster describes a modular development of a paper-based molecular diagnostic device and the latest results obtained from a proof-of-concept device.
|Differences in the Neurophysiology of Infants with Down Syndrome May Predict Protective/Risk Markers for Subsequent Alzheimer’s Disease|
Esha Massand1,2, Hana D’Souza1,2, George Ball1,2, Maria Eriksson1, Charlotte Dennison1, Joanna Ball1 & Annette Karmiloff-Smith1,2
Our work set out to understand early individual differences in memory abilities of infants with DS that may be predictive of subsequent cognitive phenotypes of AD.
|The Challenges of Genetic Testing in Patients Diagnosed with Breast Cancer; The Kent Oncology Centre Experience|
Christos Mikropoulos1,2, Aaron Davies 1, Charlotte Abson1, Gill Sadler1, Gemma McCormick1, Questa Karlsson2, Julia Hall2
In this study we explore retrospective data to determine strategies for optimizing the genetic referral pathways for breast cancer.